publication venue for
- PCN133 ECONOMIC EVALUATION OF EPIDERMAL GROWTH FACTOR RECEPTOR - TYROSINE KINASE INHIBITOR (EGFR-TKI) DRUGS IN NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT: A SYSTEMATIC REVIEW OF RECENT STUDIES. 23:s46-S46. 2020
- Medical Nutrition Terminology and Regulations in the United States and Europe—A Scoping Review: Report of the ISPOR Nutrition Economics Special Interest Group. 22:1-12. 2018
- PRM57 Classification of Causes of Hospitalization For Heart Failure Patients In Cost-Effectiveness and Cost-Utility Evaluations of Pharmacotherapeutic, Surgical, and Managed-Care Interventions: Systematic Review. 20:a740-A740. 2017
- Patient-Reported Pediatric Quality of Life Inventory™ 4.0 Generic Core Scales in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Psychiatric Disorders: Feasibility, Reliability, and Validity. 14:521-530. 2011
- PDB49 AGE-SPECIFIC ORIGINALS: USING THE PEDIATRIC QUALITY OF LIFE™ (PEDSQL™) DIABETES MODULE TO STUDY SIMILARITIES AND DIFFERENCES IN TARGET LANGUAGES. 13:a63-A63. 2010
- Statin Cost‐Effectiveness Comparisons Using Real‐World Effectiveness Data: Formulary Implications. 11:1061-1069. 2008
- Factorial Invariance of Child Self‐Report across Age Subgroups: A Confirmatory Factor Analysis of Ages 5 to 16 Years Utilizing the PedsQL 4.0 Generic Core Scales. 11:659-668. 2008
- PCV5 POTENTIAL COST SAVINGS FROM ACUTE CORONARY SYNDROME TREATMENT IMPROVEMENTS. 8:262-262. 2005
- Medical Care Costs Associated with Postmenopausal Estrogen Plus Progestogen Therapy. 7:544-553. 2004
- POS5 ECONOMIC EVALUATION OF SHORT-TERM NON-VERTEBRAL FRACTURE-RELATED COSTS AMONG OSTEOPOROSIS TREATMENTS. 7:297-297. 2004
- PHB6 Health Care Use in Women Age 45 and Older. 1:64-65. 1998
- ECONOMIC EVALUATION OF EPIDERMAL GROWTH FACTOR RECEPTOR - TYROSINE KINASE INHIBITOR (EGFR-TKI) DRUGS IN NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT: A SYSTEMATIC REVIEW OF RECENT STUDIES 2020
- PCN251 ESTIMATING QUALITY-ADJUSTED LIFE YEARS (QALYS) THROUGH QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (QTWIST) IN RCTS: AN ALTERNATIVE TO ECONOMIC MODELLING 2019
- PDB117 A NEW MODEL OF INTEGRATED CARE FOR COMPLEX TYPE 2 DIABETES IN UNDERSERVED POPULATIONS: A STUDY PROTOCOL FOR A COST-EFFECTIEVENESS ANALYSIS 2019
- PND42 COST-EFFECTIVENESS ANALYSIS OF ERENUMAB VERSUS TOPIRAMATE FOR PATIENTS WITH CHRONIC MIGRAINES TO IDENTIFY THE COST-EFFECTIVE PRICE THRESHOLD IN GREECE 2019
- PCN108 Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum Sensitive< Recurrent Ovarian Cancer 2018
- PCN54 Budget Impact Analysis of Niraparib and Olaparub As Maintenance Therapy for Platinum Sensitive, Recurrent Ovarian Cancer In The US 2018
- PRS36 Rapid Estimation of Smoking-Attributable Mortality and Economic Costs 2018
- EPIDEMIOLOGY AND ECONOMIC BURDEN OF SYSTEMIC SCLEROSIS - A SYSTEMATIC REVIEW 2017
- PDB46 UTILIZATION PATTERN OF PRESCRIPTION PAIN MEDICATION AMONG ADULTS WITH DIABETES MELLITUS 2016
- PRM62 COMPARISON OF DATA TO DECISION MODELS FOR A DATA CONSORTIA 2016
- PHS123 Do Children With Special Needs Receiving Care Coordination Have Greater Access To Primary Care? 2014
- PIH41 Are Different Spanish Versions of Pro Measures Necessary? The Case Study of the Pedsql™ 4.0 Generic Core Scales 2011
- PCN107 PAYER-RATED VALUE OF PAIN IMPROVEMENT IN CASTRATION-RESISTANT PROSTATE CANCER: TRADEOFFS BETWEEN SURVIVAL, PAIN AND ANALGESIC USE 2011
- PCV33 USE OF SECONDARY DATA SOURCES TO ESTIMATE INPATIENT COSTS AND PAYMENTS FOR ACUTE CORONARY SYNDROME 2011
- PSY14 ECONOMIC IMPACT OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PATIENTS TAKING OPIOID ANALGESICS 2011
- PSY29 A COMPARISON OF DAILY AVERAGE SUPPLY (DASUP) OF OXYCODONE AND OXYMORPHONE LONG-ACTING ORAL TABLETS 2011
- PCV70 COST-EFFECTIVENESS OF ROSUVASTATIN 20 MG IN SECONDARYPREVENTION PATIENTS IN THE UNITED STATES 2010
- PCV84 COST-EFFECTIVENESS OF ROSUVASTATIN 10 MG IN THE REDUCTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS AT RISK OF CARDIOVASCULAR DISEASE 2010
- PCV64 ECONOMIC BURDEN OF ATHEROSCLEROSIS AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS 2009
- PRS18 DIFFERENCES IN TREATMENT COSTS AND RESOURCE UTILIZATION AMONG COPD PATIENTS TREATED WITH ALBUTEROL MDI OR LEVALBUTEROL MDI 2008
- PCV16 ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE 2006
- PPN3 SUMMARY OF HOSPITAL LOGISTICS ASSOCIATED WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA (IV PCA) FOR ACUTE POSTOPERATIVE PAIN MANAGEMENT 2005
- PRK9: COST-EFFECTIVENESS OF TAMSULOSIN, DOXAZOSIN AND TERAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA 2003